[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100438113":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":26,"responsibleParty":43,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":58,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Hellenic Cooperative Oncology Group","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with breast cancer randomised in arm A of digital platform",null,"Patients with breast cancer treated with abemaciclib in combination with endocrine treatment and randomised in Arm A of the digital platform. Patients randomised in arm A will receive a an acknowledgement and suggestion to stay in contact with their clinician.",{"label":13,"type":10,"description":14,"interventionNames":10},"Patients with breast cancer randomised in arm B of digital platform","Patients with breast cancer treated with abemaciclib in combination with endocrine treatment and randomised in Arm B of the digital platform. Patients randomised in arm A will receive a an acknowledgement and suggestion to stay in contact with their clinician; additionally they will receive personalised support (as a few word text) for each side-effect reported.",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Elena Fountzilas, MD, PhD","CONTACT","+306945779709","FOUNTZILA@ONCOGENOME.GR",{"name":22,"role":18,"phone":23,"phoneExt":24,"email":25},"Areti Stamboliou","+302106912520","23","a_stampoliou@hecog.ondsl.gr",[27],{"facility":28,"status":29,"city":30,"state":10,"zip":10,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Hellenic Oncology Cooperative Group","RECRUITING","Athens","Greece","GR",{"type":34,"coordinates":35},"Point",[36,37],23.72784,37.98376,{"lat":37,"lon":36},[40],{"name":41,"role":18,"phone":10,"phoneExt":10,"email":42},"Elena Fountzilas, MD","fountzila@oncogenome.gr",{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100438113","real-world-data-in-patients-with-breast-cancer-treated-with-abemaciclib-100438113",false,"NCT04985058","Real-world Data in Patients With Breast Cancer Treated With Abemaciclib","Real-world Clinical Outcome and Toxicity Data in Patients With Breast Cancer Treated With Abemaciclib Combined With Endocrine Therapy: the Experience of the Hellenic Cooperative Oncology Group","ENDURANCE","Inclusion Criteria:\n\n* Histologically confirmed HR-positive, HER2-negative breast cancer\n* Treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology\n* 18 years or older\n* Any menopausal status\n* Treatment with abemaciclib in combination with endocrine therapy\n* Any endocrine therapy\n* At least two months of treatment with abemaciclib","ALL","18 Years",{"count":56,"type":57},108,"ESTIMATED","30 Months","OBSERVATIONAL","The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative advanced breast cancer.",[62],"Breast Cancer",[64,65],"abemaciclib","real-world data","2026-07-20",{"date":68,"type":69},"2026-07-21","ACTUAL",{"date":71,"type":69},"2021-10-06",{"date":73,"type":57},"2027-07-01",{"name":5,"class":6},1]